Author/Authors :
Gloss، نويسنده , , Brian S. and Patterson، نويسنده , , Kate I. and Barton، نويسنده , , Caroline A. and Gonzalez، نويسنده , , Maria and Scurry، نويسنده , , James P. and Hacker، نويسنده , , Neville F. and Sutherland، نويسنده , , Robert L. and O’Brien، نويسنده , , Philippa M. and Clark، نويسنده , , Susan J.، نويسنده ,
Abstract :
To identify epigenetic-based biomarkers for diagnosis of ovarian cancer we performed MeDIP-Chip in A2780 and CaOV3 ovarian cancer cell lines. Validation by Sequenom massARRAY methylation analysis confirmed a panel of six gene promoters (ARMCX1, ICAM4, LOC134466, PEG3, PYCARD & SGNE1) where hypermethylation discriminated 27 serous ovarian cancer clinical samples versus 12 normal ovarian surface epithelial cells (OSE) (ROC of 0.98). Notably, CpG sites across the transcription start site of a potential long-intergenic non-coding RNA (lincRNA) gene (LOC134466), was shown to be hypermethylated in 81% of serous EOC and could differentiate tumours from OSE (p < 0.05). We propose that this potential biomarker panel holds great promise as a diagnostic test for high-grade (Type II) serous ovarian cancer.
Keywords :
Ovarian cancer , DNA methylation , Epigenetics , microarray analysis , biomarkers
